Mild traumatic brain injury (mTBI), which throughout the literature is used
interchangeably with concussion, is a problem of public concern. It is estimated that
between 0.6 % and 1.2 % of the general population will suffer an mTBI each year which
equals to 48-96 millions of people on a world scale. Out of these, an estimated 10-30 %
of the patients, will suffer from persistent PPCS. These symptoms typically includes
headache, poor concentration, memory problems, fatigue, sleep difficulties, dizziness,
irritability, feeling nervous or anxious. PPCS has proven to be not only a health
problem, but also a socioeconomical problem. Data has showed that salary in Denmark five
years after a concussion decreased 4.2 %, with an increased risk of losing ones job. At
the moment no single treatment option is available with guaranteed success, and therefore
nutritional supplements are a possibility.
The nutritional supplement CrM is one of the most popular ergogenic aids on the market
among professional and amateur athletes. It is mostly used in the development of muscle
mass, as creatine is primarily located skeletal muscle. Roughly five percent of the
body's creatine is distributed in the brain and testicles. As mTBI's also see a change in
the metabolism of the brain, creatine supplementation might be beneficial for patients
with PPCS. This is further supported by a newly conducted study, that creatine
supplementation may reduce the severity of mild concussion in animal models.
Furthermore, as the enzyme Creatine Kinease (CK), which is involved in ATP energy system,
also has a brain specific isoform (BB-CK), creatine may be a relevant part of the energy
system of the central nervous system (CNS). In addition evidence points towards creatine
supplementation can increase cellular energy availability. It has been reported to
increase brain phosphocreatine content by as much as 15 %, which in turn improves the
metabolic processes of the brain.
CrM has been described to be a potent anti-inflammatory molecule. It has been shown to
reduce the cytotoxic effects in oxidatively-injured cells without affecting antioxidant
enzyme activities, and has been shown to inhibit reactive oxygen species-induced
formation of mitochondrial permeability transition pores in the liver mitochondria of
mice. At the same time, concussion seems to increase inflammation in the brain, and this
inflammation has been hypothesized to correlate with the symptomatology and duration. And
even though research in the area of recovery is still scarce, neuroinflammation seems to
play a vital role in the pathophysiology of concussions. This warrants hopes of a
decrease in post-concussive symptoms.
Other studies have indicated an improvement of cognitive functions, including fatigue,
working memory and mood state. All symptoms related to PPCS. Additionally evidence points
towards creatine supplementation can help with chronic fatigue, depression and anxiety.
All this points towards CrM being helpful in the treatment of PPCS.
Currently there is not viable treatment option for these patients, but if the
intervention shows positive results, patients suffering from PPCS would be able to
improve on their symptoms, relatively easy and cheap. They would have a go-to supplement,
that would make it possible for them to get a normal day, without any of the symptoms
connected to PPCS.
The pilot study will be performed as a randomized controlled trial in accordance with the
Spirit Guidelines. The study is expected to include a convenience sample of 45 patients.
The patients will randomly be allocated to either a control group, placebo group or
intervention group, with 15 patients in each. The study will be double blinded, i.e., the
participants and personel not knowing which group the patients will be allocated to.
Furthermore, the process of randomization will consist of a nutritionist not otherwise
associated with the study, randomly allocating each participant in a group, until sample
size is reached. The person in charge of this, will also be distributing either the
placebo or the CrM to the participants in each of these groups.
CG will not receive any treatment other than usual treatment. PLA and INT will both
receive a powder, that has to be ingested. PLA will receive a powder similar in looks to
CrM, but with no apparent nutritional value, while INT will receive CrM.
As both PLA and INT are the interventions, they will follow the same protocol for
ingestion: 5 grams pr day in seven weeks. All 5 grams will be ingested at once. This
protocol has been chosen instead of the more common 0.3 g/day for the first week,
ingested over five times during the day. In other studies on CrM and the brain, this have
been the chosen strategy also. But studies on CrM in the muscles show, that both
protocols illicit the same response with 28 days, and the loading phase is not required.
Furthermore, some studies have used this protocol with creatine supplementation, and
found increased cognitive function. Our reason for choosing 5 g/day in seven weeks, is to
increase the chances of compliance, and decrease the risks of discomfort with to high an
intake of CrM. An intake five times a day for the first week, is demanding, and will most
likely get some participants to quit the study.
At the mid phase of the study, all baseline measurements will be done again. The length
of the intervention is seven weeks. After the seven weeks, all baseline measurements will
be done again. And a week after last ingestion, the measurements will be done one last
time. At the week eight appointment, every participant will have to answer whether they
thought they were getting placebo or CrM. This is done in order to figure out how big an
effect placebo have on the results.
The control group will receive standard care. However, to our knowledge there is no
common accepted description of a standard care in the literature., In general, these
participants will be advised to keep themselves as asymptomatic as possible throughout
the entire seven weeks, and besides that live as normal a life as they can.
The study population will be patients with persistent post-concussive symptoms between
six and twelve months at start of participation. Participants will be recruited through
social media and fourteen neurological outpatient clinics located in Denmark. At the
start of the study, participants will have to be between 25 and 35 years of age. This
will make the population a homogenous age group, and we will avoid physical and cognitive
challenges related to early childhood and adolescents, as well as avoiding the
degeneration in physical capacities that begin at approximately the age of 35, as well as
the cognitive decline around the same time.
The anthropometrics of the participants will consist of age (years), gender
(male/female), height (cm), bodymass (kg), period with PPCS (months), concussion history
(yes/no), if yes, then how many (number), and training status (hours/week).
